Search results
Results From The WOW.Com Content Network
CIPN involves various symptoms such as tingling, pain, and numbness in the hands and feet. [2] These symptoms can impair activities of daily living, such as typing or dressing, reduce balance, and increase risk of falls and hospitalizations. They can also give cause to reduce or discontinue chemotherapy.
Late-onset GM2 gangliosidosis may also present as burning dysesthesia. [6] Chemotherapy-induced peripheral neuropathy is a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs caused by some chemotherapy agents. [7]
Paresthesia, also known as pins and needles, is an abnormal sensation of the skin (tingling, pricking, chilling, burning, numbness) with no apparent physical cause. [1] Paresthesia may be transient or chronic, and may have many possible underlying causes. [1]
For premium support please call: 800-290-4726 more ways to reach us
Peripheral neuropathy may be classified according to the number and distribution of nerves affected (mononeuropathy, mononeuritis multiplex, or polyneuropathy), the type of nerve fiber predominantly affected (motor, sensory, autonomic), or the process affecting the nerves; e.g., inflammation (), compression (compression neuropathy), chemotherapy (chemotherapy-induced peripheral neuropathy).
The symptoms can occur anywhere between days to months after administration of the offending medication, depending on the dose and speed of administration. [3] [4] The patient first experiences tingling and/or numbness of the palms and soles. This is followed 2–4 days later by bright redness, which is symmetrical and sharply defined.
Hypoesthesia or numbness is a common side effect of various medical conditions that manifests as a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli. In everyday speech this is generally referred to as numbness.
According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.